22CT012: GPC2 CAR T Cell Trial
Contact
Description
The purpose of this study is to test an experimental approach called cell therapy for neuroblastoma or retinoblastoma. This study will take a patient's own white blood cells (T cells) and change them to turn against the cancer. These cells are an experimental treatment and have not been approved by the FDA. CAR T cells have been used to treat other cancers, but GPC2 CAR T cells have not been administered to human patients prior to this clinical trial.
If they choose to participate in this study, active participation will last approximately 12 months. Participants will also be asked to sign consent to a separate long term follow-up protocol to monitor their health for up to 15 years after their last GPC2 CAR T treatment.
This study will assess the safety and effectiveness of GPC2 CAR T cells. Overall, approximately 45 subjects will be enrolled on this study.
Eligibility and criteria
What to expect
This study will take place at the Children's Hospital of Philadelphia.
Active participation lasts for 12 months. Study visits will occur at the following cadence: Screening/Enrollment, Pre-Infusion, Day -1, Infusion (Day 0), Day 1, Day 3, Day 7, Day 10, Day 14, Day 21, Day 28, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, and Month 12
Possible procedures include:
- medical record review
- apheresis
- GPC2 CAR T cell infusion
- blood draws
- physical exams
- imaging
- disease assessments through bone marrows and lumbar punctures
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.